Janssen hopes for Invega approval for the holidays
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Johnson & Johnson subsidiary's NDA for the antipsychotic Invega (paliperidone extended-release) has a Dec. 20 user fee goal date, J&J said Nov. 10 after submitting a response to FDA's Sept. 29 "approvable" letter (1Pharmaceutical Approvals Monthly October 2006, In Brief)...
You may also be interested in...
J&J paliperidone ER "approvable"
Johnson & Johnson's extended-release schizophrenia agent paliperidone is "approvable" Sept. 29; J&J says it will "work quickly to resolve the agency's questions." Earlier in September, the company had indicated that it expected an approvable decision. J&J submitted the follow-on compound to its blockbuster atypical antipsychotic Risperdal (risperidone) in December 2005 (1Pharmaceutical Approvals Monthly December 2005, In Brief)...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: